브루가다 증후군 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Brugada Syndrome Market - Scope of Report

TMR's report on the global brugada syndrome market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global brugada syndrome market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global brugada syndrome market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the brugada syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global brugada syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global brugada syndrome market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global brugada syndrome market.

The report delves into the competitive landscape of the global brugada syndrome market. Key players operating in the global brugada syndrome market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global brugada syndrome market profiled in this report.

Key Questions Answered in Global brugada syndrome Market Report:

• What is the sales/revenue generated by brugada syndrome across all regions during the forecast period?
• What are the opportunities in the global brugada syndrome market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Brugada Syndrome Market - Research Objectives and Research Approach

The comprehensive report on the global brugada syndrome market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global brugada syndrome market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global brugada syndrome market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Brugada Syndrome Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Brugada Syndrome Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Brugada Syndrome Market Analysis and Forecast, by Diagnosis Methods

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Diagnosis Methods, 2020-2034
  • 6.3.1. Electrocardiogram (ECG)
  • 6.3.2. Echocardiogram
  • 6.3.3. Electrophysiological (EP) Testing and Mapping
  • 6.3.4. Others (Genetic Testing, etc.)
• 6.4. Market Attractiveness, by Diagnosis Methods

7. Global Brugada Syndrome Market Analysis and Forecast, by Treatment Type

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 7.3.1. Surgical Methods
    • 7.3.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
    • 7.3.1.2. Radiofrequency Catheter Ablation
  • 7.3.2. Drug Therapy
    • 7.3.2.1. Antiarrhythmic Drugs
    • 7.3.2.2. Psychotropic Drugs
    • 7.3.2.3. Analgesic Drugs
    • 7.3.2.4. Others (beta-blockers, etc.)
• 7.4. Market Attractiveness, by Treatment Type

8. Global Brugada Syndrome Market Analysis and Forecast, by Indication Type

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Indication Type, 2020-2034
  • 8.3.1. Brugada Type 1
  • 8.3.2. Brugada Type 2
• 8.4. Market Attractiveness, by Indication Type

9. Global Brugada Syndrome Market Analysis and Forecast, by End-user

• 9.1. Introduction and Definitions
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by End-user, 2020-2034
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Surgical Centers
  • 9.3.3. Diagnostic Centers
  • 9.3.4. Others (Beta-blockers, etc.)
• 9.4. Market Attractiveness, by End-user

10. Global Brugada Syndrome Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2020-2034
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness, by Region

11. North America Brugada Syndrome Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
  • 11.2.1. Electrocardiogram (ECG)
  • 11.2.2. Echocardiogram
  • 11.2.3. Electrophysiological (EP) Testing and Mapping
  • 11.2.4. Others (Genetic Testing, etc.)
• 11.3. Market Attractiveness, by Diagnosis Methods
• 11.4. Market Value Forecast, by Treatment Type, 2020-2034
  • 11.4.1. Surgical Methods
    • 11.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
    • 11.4.1.2. Radiofrequency Catheter Ablation
  • 11.4.2. Drug Therapy
    • 11.4.2.1. Antiarrhythmic Drugs
    • 11.4.2.2. Psychotropic Drugs
    • 11.4.2.3. Analgesic Drugs
    • 11.4.2.4. Others (beta-blockers, etc.)
• 11.5. Market Attractiveness, by Treatment Type
• 11.6. Market Value Forecast, by Indication Type, 2020-2034
  • 11.6.1. Brugada Type 1
  • 11.6.2. Brugada Type 2
• 11.7. Market Attractiveness, by Indication Type
• 11.8. Market Value Forecast, by End-user, 2020-2034
  • 11.8.1. Hospitals & Clinics
  • 11.8.2. Surgical Centers
  • 11.8.3. Diagnostic Centers
  • 11.8.4. Others (Beta-blockers, etc.)
• 11.9. Market Attractiveness, by End-user
• 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.10.1. U.S.
  • 11.10.2. Canada
• 11.11. Market Attractiveness Analysis
  • 11.11.1. By Diagnosis Methods
  • 11.11.2. By Treatment Type
  • 11.11.3. By Indication Type
  • 11.11.4. By End-user
  • 11.11.5. By Country

12. Europe Brugada Syndrome Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
  • 12.2.1. Electrocardiogram (ECG)
  • 12.2.2. Echocardiogram
  • 12.2.3. Electrophysiological (EP) Testing and Mapping
  • 12.2.4. Others (Genetic Testing, etc.)
• 12.3. Market Attractiveness, by Diagnosis Methods
• 12.4. Market Value Forecast, by Treatment Type, 2020-2034
  • 12.4.1. Surgical Methods
    • 12.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
    • 12.4.1.2. Radiofrequency Catheter Ablation
  • 12.4.2. Drug Therapy
    • 12.4.2.1. Antiarrhythmic Drugs
    • 12.4.2.2. Psychotropic Drugs
    • 12.4.2.3. Analgesic Drugs
    • 12.4.2.4. Others (beta-blockers, etc.)
• 12.5. Market Attractiveness, by Treatment Type
• 12.6. Market Value Forecast, by Indication Type, 2020-2034
  • 12.6.1. Brugada Type 1
  • 12.6.2. Brugada Type 2
• 12.7. Market Attractiveness, by Indication Type
• 12.8. Market Value Forecast, by End-user, 2020-2034
  • 12.8.1. Hospitals & Clinics
  • 12.8.2. Surgical Centers
  • 12.8.3. Diagnostic Centers
  • 12.8.4. Others (Beta-blockers, etc.)
• 12.9. Market Attractiveness, by End-user
• 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.10.1. Germany
  • 12.10.2. U.K.
  • 12.10.3. France
  • 12.10.4. Italy
  • 12.10.5. Spain
  • 12.10.6. Rest of Europe
• 12.11. Market Attractiveness Analysis
  • 12.11.1. By Diagnosis Methods
  • 12.11.2. By Treatment Type
  • 12.11.3. By Indication Type
  • 12.11.4. By End-user
  • 12.11.5. By Country/Sub-region

13. Asia Pacific Brugada Syndrome Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
  • 13.2.1. Electrocardiogram (ECG)
  • 13.2.2. Echocardiogram
  • 13.2.3. Electrophysiological (EP) Testing and Mapping
  • 13.2.4. Others (Genetic Testing, etc.)
• 13.3. Market Attractiveness, by Diagnosis Methods
• 13.4. Market Value Forecast, by Treatment Type, 2020-2034
  • 13.4.1. Surgical Methods
    • 13.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
    • 13.4.1.2. Radiofrequency Catheter Ablation
  • 13.4.2. Drug Therapy
    • 13.4.2.1. Antiarrhythmic Drugs
    • 13.4.2.2. Psychotropic Drugs
    • 13.4.2.3. Analgesic Drugs
    • 13.4.2.4. Others (beta-blockers, etc.)
• 13.5. Market Attractiveness, by Treatment Type
• 13.6. Market Attractiveness, by Treatment Type
• 13.7. Market Value Forecast, by Indication Type, 2020-2034
  • 13.7.1. Brugada Type 1
  • 13.7.2. Brugada Type 2
• 13.8. Market Attractiveness, by Indication Type
• 13.9. Market Value Forecast, by End-user, 2020-2034
  • 13.9.1. Hospitals & Clinics
  • 13.9.2. Surgical Centers
  • 13.9.3. Diagnostic Centers
  • 13.9.4. Others (Beta-blockers, etc.)
• 13.10. Market Attractiveness, by End-user
• 13.11. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.11.1. China
  • 13.11.2. Japan
  • 13.11.3. India
  • 13.11.4. Australia & New Zealand
  • 13.11.5. Rest of Asia Pacific
• 13.12. Market Attractiveness Analysis
  • 13.12.1. By Diagnosis Methods
  • 13.12.2. By Treatment Type
  • 13.12.3. By Indication Type
  • 13.12.4. By End-user
  • 13.12.5. By Country/Sub-region

14. Latin America Brugada Syndrome Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
  • 14.2.1. Electrocardiogram (ECG)
  • 14.2.2. Echocardiogram
  • 14.2.3. Electrophysiological (EP) Testing and Mapping
  • 14.2.4. Others (Genetic Testing, etc.)
• 14.3. Market Attractiveness, by Diagnosis Methods
• 14.4. Market Value Forecast, by Treatment Type, 2020-2034
  • 14.4.1. Surgical Methods
    • 14.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
    • 14.4.1.2. Radiofrequency Catheter Ablation
  • 14.4.2. Drug Therapy
    • 14.4.2.1. Antiarrhythmic Drugs
    • 14.4.2.2. Psychotropic Drugs
    • 14.4.2.3. Analgesic Drugs
    • 14.4.2.4. Others (beta-blockers, etc.)
• 14.5. Market Attractiveness, by Treatment Type
• 14.6. Market Value Forecast, by Indication Type, 2020-2034
  • 14.6.1. Brugada Type 1
  • 14.6.2. Brugada Type 2
• 14.7. Market Attractiveness, by Indication Type
• 14.8. Market Value Forecast, by End-user, 2020-2034
  • 14.8.1. Hospitals & Clinics
  • 14.8.2. Surgical Centers
  • 14.8.3. Diagnostic Centers
  • 14.8.4. Others (Beta-blockers, etc.)
• 14.9. Market Attractiveness, by End-user
• 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.10.1. Brazil
  • 14.10.2. Mexico
  • 14.10.3. Rest of Latin America
• 14.11. Market Attractiveness Analysis
  • 14.11.1. By Diagnosis Methods
  • 14.11.2. By Treatment Type
  • 14.11.3. By Indication Type
  • 14.11.4. By End-user
  • 14.11.5. By Country/Sub-region

15. Middle East & Africa Brugada Syndrome Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Diagnosis Methods, 2020-2034
  • 15.2.1. Electrocardiogram (ECG)
  • 15.2.2. Echocardiogram
  • 15.2.3. Electrophysiological (EP) Testing and Mapping
  • 15.2.4. Others (Genetic Testing, etc.)
• 15.3. Market Attractiveness, by Diagnosis Methods
• 15.4. Market Value Forecast, by Treatment Type, 2020-2034
  • 15.4.1. Surgical Methods
    • 15.4.1.1. Implantable Cardiovascular Defribrillator (ICD) Placement
    • 15.4.1.2. Radiofrequency Catheter Ablation
  • 15.4.2. Drug Therapy
    • 15.4.2.1. Antiarrhythmic Drugs
    • 15.4.2.2. Psychotropic Drugs
    • 15.4.2.3. Analgesic Drugs
    • 15.4.2.4. Others (beta-blockers, etc.)
• 15.5. Market Attractiveness, by Treatment Type
• 15.6. Market Value Forecast, by Indication Type, 2020-2034
  • 15.6.1. Brugada Type 1
  • 15.6.2. Brugada Type 2
• 15.7. Market Attractiveness, by Indication Type
• 15.8. Market Value Forecast, by End-user, 2020-2034
  • 15.8.1. Hospitals & Clinics
  • 15.8.2. Surgical Centers
  • 15.8.3. Diagnostic Centers
  • 15.8.4. Others (Beta-blockers, etc.)
• 15.9. Market Attractiveness, by End-user
• 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 15.10.1. GCC Countries
  • 15.10.2. South Africa
  • 15.10.3. Rest of Middle East & Africa
• 15.11. Market Attractiveness Analysis
  • 15.11.1. By Diagnosis Methods
  • 15.11.2. By Treatment Type
  • 15.11.3. By Indication Type
  • 15.11.4. By End-user
  • 15.11.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2023)
• 16.3. Company Profiles
  • 16.3.1. GeneDx, LLC
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. GE HealthCare
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. GSK plc
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Lilly India
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Boston Scientific Corporation
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Pfizer Inc.
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview